Johnson & Johnson: Urinary Bladder Neoplasms trials

The registry lists 12 Urinary Bladder Neoplasms studies with Johnson & Johnson as lead sponsor. 2 are open to participants now and 3 have results posted.

Phase 1 5Phase 2 3Phase 3 2No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study to Characterize High-Risk Non-Muscle-Invasive Bladder Cancer Participants in PortugalRecruitingNCT07784387
• A Study of Radical Cystectomy in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) and Muscle Invasive Bladder Cancer (MIBC) in KoreaNot yet recruitingNCT07735793
• A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the BladderCompletedNCT04919512Phase 2Results posted
• A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical CystectomyActive, not recruitingNCT04640623Phase 2Results posted
• A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)CompletedNCT04172675Phase 2Results posted
• A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)Active, not recruitingNCT05714202Phase 3
• A Study of Erdafitinib Intravesical Delivery System in Japanese Participants With Bladder CancerActive, not recruitingNCT05567185Phase 1
• A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the BladderActive, not recruitingNCT04658862Phase 3
• Safety and Tolerability of TAR-200 and Nivolumab in Subjects With Muscle-Invasive Bladder CancerTerminatedNCT03518320Phase 1
• A Study of TAR-200 in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder Who Are Ineligible for or Refuse Cisplatin-based Chemotherapy and Who Are Unfit for Radical CystectomyCompletedNCT03404791Phase 1
• Safety and Tolerability of GemRIS 225 mg in Subjects With Muscle-Invasive Bladder CancerCompletedNCT02722538Phase 1
• Safety and Tolerability of TAR-200 mg in Subjects With Non-Muscle-Invasive Bladder CancerCompletedNCT02720367Phase 1